Triple therapy effective in cirrhotic patients with HIV/HCV

Joop Arends, MD, PhD, an infectious disease specialist at the University Medical Center Utrecht in the Netherlands, discusses his presentation at EACS 2013 on the effect of triple therapy (telaprevir or boceprevir with pegylated interferon and ribavirin) on HIV/HCV coinfected patients with cirrhosis. In the study, triple therapy using either telaprevir or boceprevir was effective at 24 weeks, but severe anemia was common in the cohort.

http://video.healio.com/video/Triple-therapy-effective-in-cir